Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Frontage Holdings Buys BRI Biopharma, a Canada/US CRO

publication date: Dec 18, 2019

Frontage Holdings (HK: 1521), a US-China CRO, acquired a Vancouver, Canada CRO, BRI Biopharma, which provides pre-clinical and clinical services. Twenty years ago, BRI was founded by Dr. David Kwok, who remains president. Frontage said the acquisition would expand its services to Canada and the west coast of the US. Earlier this year, Frontage completed a $205 million IPO on the Hong Kong exchange, including shares sold by China CRO Tigermed, which continues to own a 51% stake in Frontage after the transaction. Financial terms of the BRI acquisition were not disclosed. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital